Literature DB >> 26709152

Changes in prostate cancer grading: Including a new patient-centric grading system.

Oleksandr N Kryvenko1, Jonathan I Epstein2.   

Abstract

The first structured approach to grade prostate cancer based on the underlying histological architecture was developed by Donald Gleason who in 1966 proposed a morphologic classification of prostate cancer and in 1974 demonstrated its clinical significance based on prostate cancer-specific death. Contemporarily referred to as the Gleason grading system, it has gained worldwide recognition allowing a more individualized approach to patients with prostate cancer. In 2005, the International Society of Urologic Pathology (ISUP) made the first revisions to the grading system. Subsequently, based on the new discoveries in pathologic and clinical aspects of prostate cancer, as well as the changing nature of the prostate cancer in part due to a robust screening, there was a need for experts to re-visit the approach to grade prostate cancer. In November 2014, the ISUP experts and clinical leaders in prostate cancer from 17 countries conducted a consensus conference in Chicago, IL, USA. The consensus conference defined various grade patterns and proposed the adoption of a new grading system of prostate cancer. Herein, we describe the background and rationale for the changes and provide guidelines to their clinical implementation.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  gleason grade; gleason score; grade group; new; prostate cancer

Mesh:

Year:  2015        PMID: 26709152     DOI: 10.1002/pros.23142

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.

Authors:  Yu-Hsuan Joni Shao; Jian-Hua Hong; Chun-Kai Chen; Chao-Yuan Huang
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-06-03       Impact factor: 5.455

2.  An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes.

Authors:  Radka Stoyanova; Felix Chinea; Deukwoo Kwon; Isildinha M Reis; Yohann Tschudi; Nestor A Parra; Adrian L Breto; Kyle R Padgett; Alan Dal Pra; Matthew C Abramowitz; Oleksandr N Kryvenko; Sanoj Punnen; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-13       Impact factor: 7.038

Review 3.  The evolving Gleason grading system.

Authors:  Ni Chen; Qiao Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

4.  Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer.

Authors:  Rogier R Wildeboer; Arnoud W Postema; Libertario Demi; Maarten P J Kuenen; Hessel Wijkstra; Massimo Mischi
Journal:  Eur Radiol       Date:  2016-12-21       Impact factor: 5.315

Review 5.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2016-09-27

6.  Automatic Detection of Prostate Tumor Habitats using Diffusion MRI.

Authors:  Yohann Tschudi; Alan Pollack; Sanoj Punnen; John C Ford; Yu-Cherng Chang; Nachiketh Soodana-Prakash; Adrian L Breto; Deukwoo Kwon; Felipe Munera; Matthew C Abramowitz; Oleksandr N Kryvenko; Radka Stoyanova
Journal:  Sci Rep       Date:  2018-11-14       Impact factor: 4.379

7.  Predicting Insignificant Prostate Cancer: Analysis of the Pathological Outcomes of Candidates for Active Surveillance according to the Pre-International Society of Urological Pathology (Pre-ISUP) 2014 Era Versus the Post-ISUP2014 Era.

Authors:  Mun Su Chung; Nam Hoon Cho; Jinu Kim; Youngheun Jo; Byung Il Yoon; Seung Hwan Lee
Journal:  World J Mens Health       Date:  2020-07-01       Impact factor: 5.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.